Dana-Farber Cancer Institute Boston, MA, USA
The Romee lab described human memory-like NK cells with enhanced anti-tumor activity and in a first in human clinical trial demonstrated safety and promising activity of these cells in advanced AML patients. We are currently testing these memory-like NK cells in combination with novel immune-modulatory agents in patients with advanced malignancies including AML, MDS, platinum refractory head and neck cancer and multiple myeloma. Using flow cytometry, mass cytometry and single cell RNA sequencing on the samples collected from these studies allows us to study key aspects of the in vivo biology of the adoptively transferred memory-like NK cells and their interaction with other immune cells present in the tumor microenvironment. We hope this information will guide us in designing future NK cell based clinical protocols. The positions in this job family will assist scientists in performing scientific research, development and/or clinical tasks of varying complexity. In general, they...